ArticleMovement disorders clinical practice2026
Investigating Sleep Concerns in Cervical Dystonia.
Article in Movement disorders clinical practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHeterogenous, small cohorts, and co-occurrence of pain and psychiatric burden complicate understanding of sleep in dystonia.
objectiveTo investigate sleep concerns in cervical dystonia (CD).
methodsLongitudinal data from CD-PROBE on subjects who were toxin-naïve, new to practice, or without injections for at least 16 weeks were analyzed. Cervical Dystonia Impact Profile captured sleep disturbances. Impact of OnabotulinumtoxinA on sleep was assessed using multilevel mixed models, controlling for demographics, dystonia severity, mood, and pain.
results56% (n = 1037) reported concerns with sleep initiation, restfulness, maintenance, and total time. Initial injection led to a clear improvement in sleep. (P < 0.001) Motor severity (β: 0.20, P < 0.001), mood (β: 0.36, P < 0.001), and pain (β: 0.58, P < 0.001) predicted sleep improvement (n = 502) over three OnabotulinumtoxinA cycles.
conclusionsSleep concerns are common in CD, with initial and subsequent improvement with OnabotulinumtoxinA. Impact of mood and pain on sleep highlights the importance of non-motor features.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.